11P - Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the BiOnHER study (ID 231)
Presentation Number
11P
Speakers
Bartomeu Fullana Grimalt (Hospitalet de Llobregat, Spain)
Authors
Bartomeu Fullana Grimalt (Hospitalet de Llobregat, Spain)
Fara Brasó-Maristany (Barcelona, Spain)
Nàdia Gómez (Hospitalet de Llobregat, Spain)
Anna Petit (Hospitalet de Llobregat, Spain)
Raul Ortega (Hospitalet de Llobregat, Spain)
Maria Vicente (Hospitalet de Llobregat, Spain)
Catalina Falo (L'Hospitalet de Llobregat, Spain)
Agostina Stradella (L'Hospitalet de Llobregat, Spain)
Silvia Vazquez (L'Hospitalet de Llobregat, Spain)
Rafael Villanueva Vazquez (Hospitalet de Llobregat, Spain)
María Jesús Pla (Hospitalet de Llobregat, Spain)
Elvira Purqueras (Hospitalet de Llobregat, Spain)
Monica Calaf (Hospitalet de Llobregat, Spain)
Laia Pare Brunet (Barcelona, Spain)
Mercedes Marín-Aguilera (Barcelona, Spain)
Patricia Galván (Barcelona, Spain)
Charles M. Perou (Chapel Hill, NC, United States of America)
Patricia Villagrasa Gonzalez (Barcelona, Spain)
Aleix Prat (Barcelona, Spain)
Sonia Pernas Simon (L'Hospitalet de Llobregat, Spain)
Presentation Topic
Biomarkers and translational research and precision medicine